Trial results for the Coin2Dose study in Type 1 Diabetes were posted on ClinicalTrials.gov on 2026-02-11, showing a mean change in HbA1c of -0.09% for the intervention group.
Background
Type 1 Diabetes is a chronic autoimmune condition requiring lifelong insulin management. Adolescents with Type 1 Diabetes often face challenges with adherence to insulin regimens, particularly with insulin bolus activity, which is crucial for managing post-meal blood glucose levels. Suboptimal insulin use can lead to poor glycemic control, as measured by HbA1c, and an increased risk of long-term complications. Interventions that can improve daily insulin bolus activity are important for this population. The Coin2Dose study aimed to explore the feasibility, acceptability, and initial efficacy of using behavioral economics incentives to target daily insulin bolus scores in adolescents with suboptimal insulin use.
Trial design
This completed study, designated as Phase NA, enrolled 173 participants with Type 1 Diabetes. The trial investigated the use of behavioral economics incentives (BEI) within a novel, semi-automated intervention called Coin2Dose. The objective was to target daily insulin bolus activity and assess its impact on HbA1c in adolescents with suboptimal insulin use. The study compared the Coin2Dose intervention group against a standard care group.
Key results
The trial reported key measurements for changes in glycated hemoglobin (HbA1c) and daily insulin bolus scores:
- For Change in Glycated Hemoglobin- HbA1c (Change in A1c (%)):
- The Standard Care group showed a mean change of -0.14 (Standard Deviation 0.58).
- The Coin2Dose group showed a mean change of -0.09 (Standard Deviation 0.65).
- For Change in Daily Insulin Bolus Score (score on scale):
- The Standard Care group showed a mean change of -0.11 (Standard Deviation 0.56).
- The Coin2Dose group showed a mean change of -0.08 (Standard Deviation 0.66).
What this means
The results indicate that the Coin2Dose behavioral economics intervention led to a mean reduction in HbA1c of -0.09% and a mean reduction in daily insulin bolus score of -0.08. While both groups showed slight reductions in these metrics, the standard care group experienced a slightly greater mean reduction in HbA1c (-0.14%) and daily insulin bolus score (-0.11). These findings suggest that the Coin2Dose intervention, in its current form, did not demonstrate a superior effect on glycemic control or insulin bolus activity compared to standard care in adolescents with Type 1 Diabetes. The observed changes in both groups were minimal, highlighting the ongoing challenge of improving glycemic outcomes in this population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05280184, titled "Coin2Dose: Behavioral Economics to Promote Insulin BOLUS Activity and Improve HbA1c in Teens", were posted on 2026-02-11 on clinicaltrials.gov.